Annexon presents tanruprubart data at PNS annual meeting

Annexon (ANNX) presented oral and poster presentations highlighting improved outcomes with tanruprubart at the 2025 Peripheral Nerve Society annual meeting being held May 17-20 in Edinburgh, UK. Results of the pivotal Phase 3 trial are reinforced by an RWE study that matched tanruprubart-treated patients from the pivotal Phase 3 trial with patients predominantly from western countries included in the IGOS registry who were treated with current standard of care, intravenous immunoglobulin or plasma exchange. In the RWE study, tanruprubart showed a rapid increase in muscle function resulting in a sustained and more complete recovery compared to IVIg or PE: By Week 1, patients treated with tanruprubart showed approximately a ten-point improvement in muscle strength over patients treated with IVIg or PE, a clinically meaningful benefit as measured by Medical Research Council sumscore and an indicator for future recovery potential. Patients treated with tanruprubart were approximately three times more likely to be in a better state of health than patients on IVIg or PE on the GBS-Disability Scale at Weeks 4, 8, and 26. New Pivotal Phase 3 Trial Analyses Reinforce the Rapid and Sustained Clinical Benefits of a Single Dose of Tanruprubart. Tanruprubart 30 mg/kg halted inflammation and nerve damage resulting in clinical benefits as early as Week 1, including rapid improvements in muscle strength, mobility, balance, and coordination that were maintained through Week 26. Tanruprubart-treated patients rapidly regained the ability to move independently, do personal tasks, and return to a range of routine daily living activities Tanruprubart demonstrated a greater degree of efficacy amongst patients with disease characteristics more commonly observed in western countries, supporting the potential of tanruprubart to benefit patients worldwide.